- Home
- GSK vs NEM Comparison
GSK vs NEM Comparison
Compare GSK & NEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSK
- NEM
- Stock Information
- Founded
- GSK 1715
- NEM 1916
- Country
- GSK United Kingdom
- NEM United States
- Employees
- GSK N/A
- NEM N/A
- Industry
- GSK Biotechnology: Pharmaceutical Preparations
- NEM Precious Metals
- Sector
- GSK Health Care
- NEM Basic Materials
- Exchange
- GSK Nasdaq
- NEM Nasdaq
- Market Cap
- GSK 77.1B
- NEM 74.6B
- IPO Year
- GSK N/A
- NEM N/A
- Fundamental
- Price
- GSK $40.85
- NEM $79.27
- Analyst Decision
- GSK Hold
- NEM Buy
- Analyst Count
- GSK 2
- NEM 10
- Target Price
- GSK N/A
- NEM $73.25
- AVG Volume (30 Days)
- GSK 3.8M
- NEM 9.0M
- Earning Date
- GSK 10-29-2025
- NEM 10-22-2025
- Dividend Yield
- GSK 3.96%
- NEM 1.26%
- EPS Growth
- GSK N/A
- NEM N/A
- EPS
- GSK 1.13
- NEM 5.55
- Revenue
- GSK $43,336,073,439.00
- NEM $20,584,000,000.00
- Revenue This Year
- GSK $5.66
- NEM $12.62
- Revenue Next Year
- GSK $5.13
- NEM N/A
- P/E Ratio
- GSK $17.49
- NEM $14.38
- Revenue Growth
- GSK 0.59
- NEM 38.38
- 52 Week Low
- GSK $31.72
- NEM $36.86
- 52 Week High
- GSK $43.62
- NEM $80.07
- Technical
- Relative Strength Index (RSI)
- GSK 59.28
- NEM 78.37
- Support Level
- GSK $39.37
- NEM $75.22
- Resistance Level
- GSK $41.53
- NEM $77.30
- Average True Range (ATR)
- GSK 0.61
- NEM 1.62
- MACD
- GSK 0.11
- NEM 0.28
- Stochastic Oscillator
- GSK 76.38
- NEM 91.34
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
About NEM Newmont Corporation
Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 17 wholly or majority owned mines and interests in two joint ventures in the Americas, Africa, Australia and Papua New Guinea. The company is expected to sell roughly 5.6 million ounces of gold in 2025 from its core mines after selling six higher-cost, smaller mines. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves along with significant byproduct reserves at the end of December 2024.